NCT05258474View on ClinicalTrials.gov

Safety and Pharmacokinetics of Oral Controlled-ileocolonic-release Nicotinamide (CICR-NAM)

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

December 4, 2020

Primary Completion Date

March 30, 2022

Study Completion Date

March 30, 2022

Conditions
Safety IssuesPharmacokinetic
Interventions
DRUG

controlled-ileocolonic-release nicotinamide (SAD/MAD/MD)

single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)

DRUG

Immediate-release nicotinamide (SAD)

single-ascending dose (SAD)

DRUG

Placebo controlled-ileocolonic-release nicotinamide (SAD/MAD)

single- and multiple-ascending dose (SAD/MAD)

DRUG

Placebo Immediate-release nicotinamide (SAD)

single-ascending dose (SAD)

Trial Locations (1)

Unknown

University Medical Center Schleswig-Holstein, Kiel

All Listed Sponsors
lead

University Hospital Schleswig-Holstein

OTHER

NCT05258474 - Safety and Pharmacokinetics of Oral Controlled-ileocolonic-release Nicotinamide (CICR-NAM) | Biotech Hunter | Biotech Hunter